Szymański Łukasz, Matak Damian, Bartnik Ewa, Szczylik Cezary, Czarnecka Anna M
Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland; Institute of Genetics and Biotechnology, Faculty of Biology, Warsaw University, Pawinskiego 5a, 02-106 Warsaw, Poland; Department of Microwave Safety, Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland.
Department of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland; School of Molecular Medicine, Medical University of Warsaw, Zwirki i Wigury 61, 02-091 Warsaw, Poland.
J Signal Transduct. 2016;2016:1362407. doi: 10.1155/2016/1362407. Epub 2016 Mar 13.
It is known that thyroid hormone is an important regulator of cancer development and metastasis. What is more, changes across the genome, as well as alternative splicing, may affect the activity of the thyroid hormone receptors. Mechanism of action of the thyroid hormone is different in every cancer; therefore in this review thyroid hormone and its receptor are presented as a regulator of renal cell carcinoma.
众所周知，甲状腺激素是癌症发展和转移的重要调节因子。此外，基因组的变化以及可变剪接可能会影响甲状腺激素受体的活性。甲状腺激素在每种癌症中的作用机制都不同；因此，在本综述中，甲状腺激素及其受体被视为肾细胞癌的一种调节因子。
